Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

12 Oct 2017

Abstract excerpt

Abstract Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction. Experimental Design: We evaluated the effect of daratumumab alone or in combination with lenalidomide-dexamethasone, on CD38 levels of multiple myeloma cells and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29025767
DOI: 10.1158/1078-0432.ccr-17-2027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabPMID 29025767Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read ↗

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detectionSemantic proximity Read ↗

Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.Semantic proximity Read ↗

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patientsSemantic proximity Read ↗

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myelomaSemantic proximity Read ↗

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumabSemantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.